Key facts
- Centauri Therapeutics’s last known valuation is $15.8M (Aug 2020).
- It has raised $46.0M; the latest was Later Stage VC ($35.5M) in Feb 2026.
- Notable investors include Innovate UK, Boehringer Ingelheim Venture Fund, CARB-X, Discovery Park Ventures, AMR Action Fund — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Centauri Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Centauri Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Centauri Therapeutics
Operator of a biotechnology company intended to discover and develop novel molecules and immunotherapy targeting life-threatening diseases. The company uses alphamer technology, in which chemically synthesized molecules redirect naturally occurring antibodies to selected pathogens to fight infections, enabling doctors to treat infectious diseases efficiently.
- Sector
- Healthcare
- HQ
- Nether Alderley, United Kingdom
- Founded
- 2014
- Employees
- 19
- Website
- centauritherapeutics.com/
- Ownership
- Privately Held (backing)
Centauri Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Centauri Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Centauri Therapeutics in its N-PORT filings yet. We sweep new filings monthly.